180 Life Sciences Corp.
ATNF
$0.83
-$0.037-4.27%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 100.14% | 73.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 68.73% | 43.64% | |||
| Operating Income | -68.73% | -43.64% | |||
| Income Before Tax | 48.15% | -446.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.56% | -410.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.56% | -410.76% | |||
| EBIT | -68.73% | -43.64% | |||
| EBITDA | -69.44% | -44.21% | |||
| EPS Basic | 93.89% | -1,183.42% | |||
| Normalized Basic EPS | 75.30% | -204.13% | |||
| EPS Diluted | 93.88% | -1,183.42% | |||
| Normalized Diluted EPS | 75.30% | -204.13% | |||
| Average Basic Shares Outstanding | 215.47% | 14.41% | |||
| Average Diluted Shares Outstanding | 215.47% | 14.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||